Concordância interobservador na interpretação imuno-histoquímica da superexpressão do Her2 detectada por cinco diferentes anticorpos em array de carcinomas mamários

Nunes, Cristiana Buzelin; Gouvêa, Agostinho Pinto; Tafuri, Luciene Simões de Assis; Marinho, Vanessa Fortes Zschaber; Rezende, Marina Alvarenga; Gobbi, Helenice

doi:10.1590/s1676-24442007000500011

Cited by 3 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The SP3, HercepTest and A0485 identified all cases with HER2 amplification using the current guidelines for Her2 assessment. However, the SP3 and the polyclonal antibodies, including the HercepTest, detected more false-positive cases than mouse monoclonal antibodies CB11 and 4D5 (20,38,39) .…”

Section: Her2/neumentioning

confidence: 90%

“…However the HercepTest, CB11 and 4D5 show higher "specificity" than SP3 for the identification of HER2 gene amplification (20,38) . Ricardo et al (43) also compared SP3 with CB11, having CISH as the gold standard in breast cancer tissue microarrays, however they showed a high specificity and a moderate sensitivity of SP3 (43) .…”

Section: Her2/neumentioning

confidence: 97%

“…This immunohistochemical Her2 scoring is based on the proportion and the intensity of cell membrane staining. But inter and intraobserver variations have been demonstrated on determination of Her2 overexpression, especially on intermediate categories (38) . When IHC results are compared with those obtained by FISH analysis, it appears that the IHC technique is associated with a significant number of false positives, particularly those represented by grade 2+ scored using the HercepTest system (21) .…”

Section: Her2/neumentioning

confidence: 99%

“…We also compared the immunohistochemical protein overexpression of protein with the gene amplification using CISH (20,38,39) . The antibody SP3 displayed an optimal "sensitivity", similar to that obtained with anti-Her2 polyclonal antibodies (i.e.…”

Section: Her2/neumentioning

confidence: 99%

“…We also evaluated interobserver variation in Her2 interpretation in IHC slides. The quality of immunostainings and the experience of the observers influence Her2 evaluation in tissue sections (38) .…”

Section: Her2/neumentioning

confidence: 99%

See 4 more Smart Citations

Predictive factors of breast cancer evaluated by immunohistochemistry

Gobbi¹,

Nunes²

2008

J. Bras. Patol. Med. Lab.

Self Cite

View full text Add to dashboard Cite

Hormone receptor and Her2 protein overexpression evaluated by immunohistochemistry (IHC) is widely validated as a predictive factor in breast cancer. The quality of the IHC reaction is influenced by tissue fixation and processing. Over-and underfixation deeply affect IHC results. Antigen retrieval may improve IHC but it does not recover tissue from autolysis or overfixation. The choice of primary antibody for IHC as to its sensitivity and specificity in relation to therapeutic response represents an important stage. Apart from mouse monoclonal antibodies, new rabbit monoclonal antibodies are commercially available, such as clones anti-ER SP1 and B644, anti-PR SP2 and B645 and anti-Her2 SP3 and 4B5. They represent an alternative to hormone receptor and Her2 evaluation by IHC. New polymeric nonbiotinylated detection systems are also available and allow accurate and strong marking with no stromal and no non-specific cytoplasmic staining due to endogenous biotin. The most recommended cut off for estrogen and progesterone receptors (ER and PR) is more than 1% of positive cells with moderate or strong staining intensity (Allred's scoring system). New guidelines for Her2 evaluation by IHC show a cut off of more than 30% of positive cells with strong intensity (3+) that correlates better with gene amplification. The 2+ cases are now considered indeterminate and should be confirmed by fluorescence in situ hybridisation (FISH)

show abstract

Section: Her2/neumentioning

confidence: 90%

Section: Her2/neumentioning

confidence: 97%

Section: Her2/neumentioning

confidence: 99%

Section: Her2/neumentioning

confidence: 99%

Section: Her2/neumentioning

confidence: 99%

See 3 more Smart Citations

Predictive factors of breast cancer evaluated by immunohistochemistry

Gobbi¹,

Nunes²

2008

J. Bras. Patol. Med. Lab.

Self Cite

View full text Add to dashboard Cite

show abstract

Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer

Nunes¹,

Sanches²,

Rocha³

et al. 2009

Rev. Assoc. Med. Bras.

Self Cite

View full text Add to dashboard Cite

SUMMARYBACKGROUND. Novel rabbit monoclonal antibodies (RabMab) for estrogen (ER), progesterone (PR) receptors and HER2 evaluation by immunohistochemistry have recently been commercially released. We compared the RabMab anti-ER, anti-PR and anti-HER2 to mouse monoclonal antibodies (Mab) using tissue microarrays (TMA) of breast carcinomas. METHODS. Two TMA containing breast carcinomas were built. Sections were immunostained using anti-ER and anti-PR, Mab and RabMab. The sections stained for ER and PR were evaluated considering positive those tumors in which more than 1% of the tumor cell nuclei stained moderate or strong. For HER2, the immunostained sections were evaluated using the ASCO/CAP guidelines for HER2. Chromogenic in situ hybridization (CISH) was used as the gold standard for HER2 evaluation. CISH was evaluated using the Zymed HER2 CISH interpretation guidelines. RESULTS. RabMab against ER have similar staining patterns compared to the 6F11 (Mab), but stronger than 1D5 (Mab) from three different suppliers. The RabMab against PR provide stronger and sharper immunohistochemical signals compared to Mab. The detection of HER2 protein overexpression was more prevalent with the polyclonal antibodies and RabMab than with the Mab. These were more specific than the RabMab, which were more sensitive when compared to CISH. CONCLUSION. The novel RabMab against ER and PR showed higher intensity of staining than the Mab. The RabMab against HER2 is more sensitive than Mab, however, Mab presented more specificity than RabMab when compared to CISH for HER2 evaluation of breast carcinomas.

show abstract

Contribuição da imuno-histoquímica na avaliação de fatores prognósticos e preditivos do câncer de mama e no diagnóstico de lesões mamárias

Salles¹,

Cúrcio

Perez³

et al. 2009

J. Bras. Patol. Med. Lab.

Self Cite

View full text Add to dashboard Cite

Objetivo: Fazer análise crítica da contribuição da imuno-histoquímica na avaliação de fatores preditivos/ prognósticos do câncer de mama, na pesquisa de micrometástases em linfonodos sentinela e no diagnóstico diferencial de lesões mamárias. Métodos: Foi realizado estudo observacional retrospectivo de todos os casos de lesões mamárias e linfonodos sentinelas submetidas a estudo imuno-histoquímico J Bras Patol Med Lab • v. 45 • n. 3 • p. 213-222 • junho 2009

show abstract

Concordância interobservador na interpretação imuno-histoquímica da superexpressão do Her2 detectada por cinco diferentes anticorpos em array de carcinomas mamários

Cited by 3 publications

References 21 publications

Predictive factors of breast cancer evaluated by immunohistochemistry

Predictive factors of breast cancer evaluated by immunohistochemistry

Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer

Contribuição da imuno-histoquímica na avaliação de fatores prognósticos e preditivos do câncer de mama e no diagnóstico de lesões mamárias

Contact Info

Product

Resources

About